GO
Loading...

Medicine

More

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Jamie Dimon said he has been diagnosed with throat cancer but that the ailment is curable and he plans to remain actively involved in the business and continue to run the largest U.S. bank.

  • JPMorgan CEO to get treatment for throat cancer Tuesday, 1 Jul 2014 | 7:23 PM ET

    NEW YORK— JPMorgan Chase CEO Jamie Dimon, a feisty leader who steered the banking company through the perils of the Great Recession, is battling throat cancer. The condition is considered to be curable, according to a memo to JPMorgan Chase& Co. employees and shareholders that Dimon released late Tuesday.

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Jamie Dimon told the bank's employees and shareholders on Tuesday that he has been diagnosed with curable throat cancer. Dimon has notified JPMorgan's board. Dimon became chairman of the board on Dec. 31, 2006, and has been CEO and president since Dec. 31, 2005.

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Officer Jamie Dimon has told the bank's employees and shareholders he has been diagnosed with curable throat cancer, Dow Jones reported on Tuesday. Dimon has notified JPMorgan's board, Dow Jones added. A JPMorgan spokeswoman did not immediately respond to a request for comment.

  • GENEVA, July 1- The number of deaths attributed to an epidemic of Ebola virus in Guinea, Liberia and Sierra Leone stood at 467 by Monday, out of 759 known cases in total, the World Health Organization said on Tuesday.

  • July 1- Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

  • AGENUS BRAIN CANCER VACCINE NEARLY DOUBLES SURVIVAL RATE IN. July 1- Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

  • Pro-life and pro-choice demonstrators eagerly awaited the U.S. Supreme Court decision on contraception on Monday. CNBC's Hampton Pearson reports on the ruling.

  • BUZZ-DICERNA PHARMACEUTICALS INC: PROMISING ANIMAL TRIAL DATA@** Drug developer's shares up 13 pct at $21.35. **Company presents positive preclinical data on its experimental liver disease drug. **The animal trials showed that Dicerna's drug blocked a gene that is found in patients with a rare inherited liver disorder called PH1.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.

  • Acorda's multiple sclerosis drug faces generic threat Thursday, 26 Jun 2014 | 6:36 AM ET

    June 26- Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra. Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.

  • Cancer drug setback tarnishes AstraZeneca's R&D claims Thursday, 26 Jun 2014 | 6:31 AM ET

    *AstraZeneca mis-steps may revive prospects of takeover. LONDON, June 26- A vote by U.S. experts against accelerated approval of a new ovarian cancer drug from AstraZeneca has dented its claims of research prowess, which were used to see off a $118 billion bid from Pfizer.

  • WASHINGTON, June 25- An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

  • WASHINGTON, June 25- An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

  • FDA PANEL VOTES 11-2 THAT AGENCY SHOULD WAIT FOR STUDY KNOWN AS SOLO-2 BEFORE GRANTING APPROVAL TO ASTRAZENECA'S OVARIAN CANCER DRUG.

  • FDA PANEL SAYS SAFETY AND EFFICACY RESULTS FOR ASTRAZENECA'S OVARIAN CANCER DRUG OLAPARIB DO NOT SUPPORT ACCLERATED APPROVAL BASED ON STUDY 19.

  • June 24- A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.

  • Vertex CEO on big cystic fibrosis breakthrough     Tuesday, 24 Jun 2014 | 3:37 PM ET

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Vertex soars on cystic fibrosis innovation     Tuesday, 24 Jun 2014 | 10:54 AM ET

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.

  • Cubist advances Sivextro     Monday, 23 Jun 2014 | 3:38 PM ET

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.